Close
Novotech
Jabsco PureFlo 21 Single Use

Press Releases

Italvacuum to Attend India CHEM 2010

We are pleased to announce that Italvacuum is participating India CHEM 2010, the largest event of the chemical and petrochemical industry in India. The 6th edition of this international conference and exhibition will take place in...

AVEVA to Exhibit at Drug Delivery Partnerships 2011

Aveva Drug Delivery Systems is pleased to announce that it will exhibit at Drug Delivery Partnerships on 26-28 January 2011 in Miami, Florida, US. Aveva Drug Delivery Systms is part of the Nitto Denko Group of ...

APR and Labtec enter into exclusive License Agreement with Ferrer International

APR and its development partner Labtec have entered into an exclusive licensing agreement with the leading European pharmaceutical company Ferrer Internacional (Ferrer) for the promotion, distribution and marketing of Donepezil Oral Dispersible Film (ODF) in Spain, Portugal and Germany....

Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial

Genzyme Corporation reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also...

Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach

NEW YORK, NY and Whitehouse Station, NJ (October 13, 2010) – Weight Watchers International, Inc., the world's leading provider of weight management services, and Merck, a global healthcare leader, announced today an innovative collaboration focused on fighting obesity. The...

Pfizer to Acquire King Pharmaceuticals, Inc.

Pfizer Inc.and King Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement.  Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash,...

ImmunoGen, Inc. Announces Positive Interim Results in Randomized Clinical Trial

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the reporting of positive interim clinical data with trastuzumab-DM1 (T-DM1) for first-line treatment of HER2+ metastatic breast cancer in a press release issued by the European...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »